CompletedNCT03993535
Predicting Treatment Response in OCD
About this title
Predicting Treatment Response in Patients With OCD
Read the official source — NCT03993535Medication studyAges 18–50Multiple countries
Understand this study
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
- Listed locations
- New York and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateStarted: October 10, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 250
- Sponsor
- University of Sao Paulo
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, Brazil, India, ...
- Age range
- From 18 Years to 50 Years
- Official registry ID
- NCT03993535
- Official title
Show the full official title
Clinical, Neurocognitive and Neuroimaging Variables Associated With Response to Treatment in Patients With OCD
Get this study by email
Recruitment & locations
CompletedNew York, United States · São Paulo, Brazil · Bangalore, India
1 more locations
- Cape Town, South Africa
Questions about this study
Who is behind this study?
The study sponsor is University of Sao Paulo, a university.
Did this study involve medication?
Yes. The study involved medication, including selective serotonin reuptake inhibitor.
Who was this study for?
This study was for people with OCD. Listed age limits: 18 years to 50 years. Other eligibility criteria applied.
